Dacarbazine
- Generic Name
- Dacarbazine
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 38
- Registration Number
- NCT04225390
- Locations
- 🇩🇪
University Hospital, Erlangen, Bavaria, Germany
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
- Conditions
- High-Risk NeuroblastomaPatient With Insufficient Response Chemoimmunotherapy
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 800
- Registration Number
- NCT04221035
- Locations
- 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹instituto Giannina Gaslini genova, Genova, Italy
A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients
- Conditions
- Melanoma (Skin)
- Interventions
- Biological: OrienX010 injection
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- OrienGene Biotechnology Ltd.
- Target Recruit Count
- 165
- Registration Number
- NCT04200040
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04067037
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
- Conditions
- Lymphocyte-Rich Classic Hodgkin LymphomaAnn Arbor Stage III Hodgkin LymphomaClassic Hodgkin LymphomaAnn Arbor Stage III Nodular Sclerosis Classic Hodgkin LymphomaAnn Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage IV Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage IV Nodular Sclerosis Classic Hodgkin LymphomaAnn Arbor Stage III Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage III Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage IV Hodgkin Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation Therapy
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 994
- Registration Number
- NCT03907488
- Locations
- 🇺🇸
The Carle Foundation Hospital, Urbana, Illinois, United States
🇺🇸Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
🇺🇸Illinois CancerCare - Washington, Washington, Illinois, United States
A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 41
- Registration Number
- NCT03761095
- Locations
- 🇺🇸
John Hopkins, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Washington University Medical Campus, Saint Louis, Missouri, United States
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
- Conditions
- Hodgkin Lymphoma
- Interventions
- Other: Quality of Life MeasurementsRadiation: Radiotherapy
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT03755804
- Locations
- 🇺🇸
Maine Children's Cancer Program, Scarborough, Maine, United States
🇺🇸St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
- Conditions
- Ann Arbor Stage IA Hodgkin LymphomaAnn Arbor Stage IIA Hodgkin LymphomaAnn Arbor Stage IB Hodgkin LymphomaAnn Arbor Stage I Lymphocyte-Depleted Classic HLAnn Arbor Stage II Hodgkin LymphomaLymphocyte-Rich Classic Hodgkin LymphomaAnn Arbor Stage IIB Hodgkin LymphomaAnn Arbor Stage II Mixed Cellularity Classic HLAnn Arbor Stage II Nodular Sclerosis Classic HLAnn Arbor Stage I Hodgkin Lymphoma
- Interventions
- Other: Quality-of-Life Assessment
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 155
- Registration Number
- NCT03712202
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT03646123
- Locations
- 🇺🇸
Texas Oncology - Flower Mound, Flower Mound, Texas, United States
🇺🇸Clinical Research Alliance - Abraham Mittelman, MD, LLC, Purchase, New York, United States
🇨🇿Fakultni Nemocnice Kralovske Vinohrady, Praha 10, Other, Czechia
OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy
- Conditions
- Classical Hodgkin LymphomaHodgkin DiseaseHodgkin LymphomaHodgkin Lymphoma (Category)
- Interventions
- First Posted Date
- 2018-05-17
- Last Posted Date
- 2019-11-18
- Target Recruit Count
- 220
- Registration Number
- NCT03527628
- Locations
- 🇸🇦
King Abdulaziz Medical City, Ministry of National Guard, Riyadh, Saudi Arabia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.